Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes
Authors:
- 1 January 2015
- journal article
- review article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 135 (1) , 31-38
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Preclinical Models Used for Immunogenicity Prediction of Therapeutic ProteinsPharmaceutical Research, 2013
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Prevention and prediction of inhibitor riskHaemophilia, 2012
- Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitizationAllergy, 2011
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-upJAMA, 2011
- Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort studyArthritis Research & Therapy, 2010
- Anti‐infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot studyThe Journal of Dermatology, 2010
- Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximabArthritis & Rheumatism, 2006
- Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profilesSeminars in Arthritis and Rheumatism, 2005
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003